Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Vaccine Market Worth $84.44 Billion by 2022

August 8, 2013

DALLAS, August 8, 2013 /PRNewswire/ –

The “Vaccine Market -By Technology & Types, Trend Analysis By Various Classes – Live /
Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic
Vaccines And By Indications – Infectious Diseases, Cancer, Allergy, Diabetes,
Cardiovascular Disease With Market Landscape Analysis – Global Forecasts To 2022″,
analyzes and studies the major market drivers, restraints, and opportunities in North
America, Europe, Asia, and the Rest of the World.

Browse

        - 22 Market Data Tables
        - 53 Figures
        - 195 Pages and an in-depth Table of Content on "Vaccine Market"

http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Early buyers will receive 10% customization on this report.

This Report studies the Global Vaccine Market, with forecast to 2022.

Within the healthcare industry, the Vaccine Market was initially considered a
low-profit venture but is currently perceived with renewed interest among industry circles
due to its high demand with respect to emerging infectious diseases. Furthermore, an
improved understanding of the immune system has paved new opportunities for developing
novel preventive and therapeutic vaccines.

This Market Research Report evaluates the Global Vaccine Market by Technology Class,
Types, End Users, Disease Indication, and Geography.

Furthermore, The Technology Class is divided into Eight Segments, namely:

        - Live/Attenuated
        - Toxoid
        - Conjugate
        - Sub-Unit
        - Recombinant Vector
        - DNA, Synthetic
        - Dentritic Vaccines.

Of the above mentioned segments, sub-unit vaccine is the largest revenue segment;
however, synthetic vaccines, recombinant vector vaccines, and DNA vaccines will be the
fastest-growing segments.

The Global Vaccine Market was valued at $27 billion in the year 2012. At the end of
2013, the market is expected to be $32.05 billion and is poised to reach approximately $84
billion by 2022, growing at a CAGR of 11.36% from 2013 to 2022.

Therapeutic vaccines, specifically targeting cancers and allergies, will offer vast
opportunities for new players entering this market. The launch of the first FDA-approved
therapeutic vaccine, Provenge by Dendreon (U.S.), for treating prostate cancer has
acknowledged the potential of vaccines in therapeutics. This scenario is expected to
further revolutionize the industry towards massive growth in the next 5 to 10 years.

The global market for vaccines is expected to grow, backed by technological
advancements with respect to the development of novel vaccines towards emerging infectious
diseases, cancers, and allergies. The market will experience continuous improvements in
vaccine design, delivery methodologies, and manufacturing in large-scale process. The
market is witnessing a trend towards development of personalized vaccines. Additionally,
the demand for safe and cost-effective drugs for the treatment of many cancers and HIV
infection, which could be addressed by therapeutic vaccines, will remarkably fuel market
growth.

North America is the largest hub for the Vaccine Market, accounting for the largest
share, followed by Europe and Asia. North America and Europe are expected to grow at a
steady pace. However, the Asia-Pacific market, particularly India and China, is expected
to witness a boost in demand and is poised to register maximum growth over the next 10
years, owing to the increase in aging population and prevalence of various infectious
diseases.

The Key Players in this Market are:

        - Novartis (Switzerland)
        - Glaxo Smith line (U.K.)
        - Merck (U.S.)
        - Sanofi (France)
        - Pfizer (U.S.)
        - Antigen Express, Inc. (U.S.)
        - Aduro Biotech (U.S.)
        - Genticel (France)
        - Biondvax (Israel)
        - Immune Targeting Systems (U.K.)
        - Prokarium (U.K.)
        - Immunobiology Ltd. (U.K.)
        - Liquidia Technologies (U.S.)
        - Alphavax (U.S.)
        - Bavarian Nordic (Denmark).

Buy a copy of this Report
@http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1155

Browse related reports to Medical Devices Market

        - Medical Power Supply Market Forecast to 2017
          @http://www.marketsandmarkets.com/Market-Reports/medical-power-supply-market-1208.html
        - Lab Automation Market Forecasts to 2017
          @http://www.marketsandmarkets.com/Market-Reports/lab-automation-market-1158.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S.
We publish strategically analyzed market research reports and serve as a business
intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and
custom research services. MarketsandMarkets covers thirteen industry verticals; including
advanced materials, automotives and transportation, banking and financial services,
biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power,
food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor
and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.

        Contact:
        Mr. Rohan
        North - Dominion Plaza
        17304 Preston Road
        Suite 800, Dallas, TX 75252
        Tel: +1-888-6006-441
        Email: sales@marketsandmarkets.com
        Visit MarketsandMarkets Blog @ http://mnmblog.org
        Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets


Source: PR Newswire